Filtered By:
Condition: Disability
Drug: Carbidopa/Levodopa

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 6 results found since Jan 2013.

Pharmacological interventions and rehabilitation approach for enhancing brain self-repair and stroke recovery.
Abstract Neuroplasticity is a natural process occurring in the brain for entire life. Stroke is the leading cause of long term disability and huge medical and financial problem throughout the world. Research conducted over the past decade focused mainly on neuroprotection in the acute phase of stroke while very little studies targets chronic stage. Recovery after stroke depends on the ability of our brain to reestablish structural and functional organization of neurovascular networks. Combining adjuvant therapies and drugs may enhance the repair processes and restore impaired brain functions. Currently, there are ...
Source: Current Neuropharmacology - July 24, 2019 Category: Drugs & Pharmacology Authors: Szelenberger R, Kostka J, Saluk-Bijak J, Miller E Tags: Curr Neuropharmacol Source Type: research

Role, indications and controversies of levodopa administration in chronic stroke patients.
Abstract Stroke leaves many patients disabled even after rehabilitative training, representing a major cause of disability. Several approaches to improve outcomes have been attempted in recent years, with only relative benefit. Emerging evidences show a potential role of pharmacological intervention to enhance motor recovery after stroke. Contrasting evidence are coming from experimental and clinical studies, so far, and pharmacological intervention during rehabilitation represents a major controversial in neurorehabilitation. Dopaminergic stimulation appears as one of the most promising way to improve motor recov...
Source: European Journal of Physical and Rehabilitation Medicine - April 5, 2013 Category: Rehabilitation Authors: Acler M, Manganotti P Tags: Eur J Phys Rehabil Med Source Type: research

The effectiveness of dopamine agonists for treatment of neuropsychiatric symptoms post brain injury and stroke.
CONCLUSION: Our systematic review demonstrates an evolving evidence base to suggest some benefits in agitation and aggression, mood and attentional deficits. However, there are key limitations of the studies undertaken to date involving small numbers of participants, heterogeneous outcome measures, and variable study designs. There is a need for on-going large prospective double-blind RCTs in these medications using standardised criteria and outcomes to fully understand their effectiveness in this patient group. PMID: 25850757 [PubMed - as supplied by publisher]
Source: Acta Neuropsychiatrica - April 11, 2015 Category: Psychiatry Tags: Acta Neuropsychiatr Source Type: research

A Kinematic Study of Progressive Micrographia in Parkinson's Disease
This study has investigated the kinematic features of progressive micrographia during a repetitive writing task. Twenty-four PD patients with duration since diagnosis of <10 years and 24 age-matched controls wrote the letter “e” repeatedly. PD patients were studied in defined off states, with scoring of motor function on the Unified Parkinson's Disease Rating Scale Part III. A digital tablet captured x-y coordinates and ink-pen pressure. Customized software recorded the data and offline analysis derived the kinematic features of pen-tip movement. The average size of the first and the last fi...
Source: Frontiers in Neurology - April 23, 2019 Category: Neurology Source Type: research

A Review of Pharmacologic Neurostimulant Use During Rehabilitation and Recovery After Brain Injury.
CONCLUSIONS: The pharmacologic agent with the most supporting literature is amantadine used for cognitive improvement after TBI. Other neurostimulants with positive, despite more limited, evidence include methylphenidate, modafinil, levodopa, and citalopram. Caution is warranted with other neurostimulants given higher rates of adverse effects or lack of benefit observed in clinical trials. PMID: 33435717 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - January 12, 2021 Category: Drugs & Pharmacology Authors: Kakehi S, Tompkins DM Tags: Ann Pharmacother Source Type: research

Dystonia and levodopa-induced dyskinesias in Parkinson's disease: Is there a connection?
Abstract Dystonia and levodopa-induced dyskinesia (LID) are both hyperkinetic movement disorders. Dystonia arises most often spontaneously, although it may be seen after stroke, injury, or as a result of genetic causes. LID is associated with Parkinson's disease (PD), emerging as a consequence of chronic therapy with levodopa, and may be either dystonic or choreiform. LID and dystonia share important phenomenological properties and mechanisms. Both LID and dystonia are generated by an integrated circuit involving the cortex, basal ganglia, thalamus and cerebellum. They also share dysregulation of striatal choliner...
Source: Neurobiology of Disease - August 20, 2019 Category: Neurology Authors: Calabresi P, Standaert DG Tags: Neurobiol Dis Source Type: research